Provost Miriam
Known title: VP of US Regulatory & FDA Rel.CIK: 0001773663
Associated companies
Transaction History
| TMDX | ▼ Sell | Gift | 1,785 | $0 | 12/15/2023 | View on chart |
| TMDX | ▼ Sell | Open Market | 206 | $15K | 12/13/2023 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 1,632 | $108K | 12/13/2023 | View on chart |
| TMDX | ▼ Sell | Open Market | 1,509 | $113K | 12/13/2023 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 3,597 | $138K | 12/13/2023 | View on chart |
| TMDX | ▼ Sell | Open Market | 2,407 | $181K | 12/13/2023 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 415 | $7K | 12/13/2023 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 3,695 | $142K | 8/31/2023 | View on chart |
| TMDX | ▼ Sell | Open Market | 2,708 | $180K | 8/31/2023 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 1,785 | $6K | 8/31/2023 | View on chart |
| TMDX | ▲ Buy | Grant | 5,685 | $0 | 2/20/2023 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 5,918 | $228K | 12/13/2022 | View on chart |
| TMDX | ▼ Sell | Open Market | 2,695 | $168K | 12/13/2022 | View on chart |
| TMDX | ▼ Sell | Open Market | 1,620 | $102K | 12/13/2022 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 1,149 | $19K | 12/9/2022 | View on chart |
| TMDX | ▼ Sell | Open Market | 3,046 | $180K | 12/9/2022 | View on chart |
| TMDX | ▼ Sell | Open Market | 567 | $33K | 12/9/2022 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 3,977 | $153K | 12/9/2022 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 2,600 | $8K | 9/2/2022 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 884 | $3K | 12/23/2021 | View on chart |
| TMDX | ▼ Sell | Open Market | 3,877 | $122K | 9/15/2021 | View on chart |
| TMDX | ▲ Buy | Option Exercise | 5,625 | $91K | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
TransMedics Group Faces Analyst Sentiment Shift
Barclays has begun covering TransMedics Group, giving it an overweight rating and a $120 price target. At the same time, Intel downgraded the company while Marvell upgraded it, showing mixed analyst views. These moves may influence how investors view the stock, especially as it trades near its 52‑week range. The company remains in a neutral technical zone with an RSI of 45 and support at $74.62.
TransMedics Group Faces Analyst Sentiment Shift. Barclays has begun covering TransMedics Group, giving it an overweight rating and a $120 price target. At the same time, Intel downgraded the company while Marvell upgraded it, showing mixed analyst views. These moves may influence how investors view the stock, especially as it trades near its 52‑week range. The company remains in a neutral technical zone with an RSI of 45 and support at $74.62.